JP2004500411A - 癌の発達の阻害のための、ブチルニトロンを含む組成物 - Google Patents
癌の発達の阻害のための、ブチルニトロンを含む組成物 Download PDFInfo
- Publication number
- JP2004500411A JP2004500411A JP2001572094A JP2001572094A JP2004500411A JP 2004500411 A JP2004500411 A JP 2004500411A JP 2001572094 A JP2001572094 A JP 2001572094A JP 2001572094 A JP2001572094 A JP 2001572094A JP 2004500411 A JP2004500411 A JP 2004500411A
- Authority
- JP
- Japan
- Prior art keywords
- pbn
- tert
- development
- nitrone
- diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011161 development Methods 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 30
- 201000011510 cancer Diseases 0.000 title claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 title claims description 19
- YUKIAUPQUWVLBK-UHFFFAOYSA-N n-pentylidenehydroxylamine Chemical compound CCCCC=NO YUKIAUPQUWVLBK-UHFFFAOYSA-N 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- IYSYLWYGCWTJSG-XFXZXTDPSA-N n-tert-butyl-1-phenylmethanimine oxide Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=CC=C1 IYSYLWYGCWTJSG-XFXZXTDPSA-N 0.000 claims abstract description 158
- 235000005911 diet Nutrition 0.000 claims abstract description 104
- 230000037213 diet Effects 0.000 claims abstract description 99
- 230000018109 developmental process Effects 0.000 claims abstract description 32
- 239000002516 radical scavenger Substances 0.000 claims abstract description 18
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940123457 Free radical scavenger Drugs 0.000 claims abstract description 14
- 230000000378 dietary effect Effects 0.000 claims abstract description 5
- 230000005748 tumor development Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 30
- 230000004730 hepatocarcinogenesis Effects 0.000 claims description 19
- 230000003217 anti-cancerogenic effect Effects 0.000 claims description 11
- PSYHRZCRICXGJJ-WQLSENKSSA-N alpha-(4-hydroxyphenyl)-N-tert-butylnitrone Chemical compound CC(C)(C)[N+](\[O-])=C\C1=CC=C(O)C=C1 PSYHRZCRICXGJJ-WQLSENKSSA-N 0.000 claims description 10
- RWHHJPINUDSOJL-UHFFFAOYSA-N n-tert-butyl-1-(3-hydroxyphenyl)methanimine oxide Chemical compound CC(C)(C)[N+]([O-])=CC1=CC=CC(O)=C1 RWHHJPINUDSOJL-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 6
- 230000000711 cancerogenic effect Effects 0.000 claims description 6
- -1 2-sulfoxyphenyl Chemical group 0.000 claims description 4
- 231100000315 carcinogenic Toxicity 0.000 claims description 4
- HGLLGCIZHHMQDE-UHFFFAOYSA-N CC(C)(C)[N+]([O-])=CC1=CC=CC=C1O Chemical compound CC(C)(C)[N+]([O-])=CC1=CC=CC=C1O HGLLGCIZHHMQDE-UHFFFAOYSA-N 0.000 claims description 3
- 230000009469 supplementation Effects 0.000 claims description 3
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 239000005428 food component Substances 0.000 claims description 2
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- LFBIMWGFXCMLMP-UHFFFAOYSA-N n-tert-butyl-1-(2-sulfooxyphenyl)methanimine oxide Chemical compound CC(C)(C)[N+]([O-])=CC1=CC=CC=C1OS(O)(=O)=O LFBIMWGFXCMLMP-UHFFFAOYSA-N 0.000 claims 1
- PVMBWGUNDZTWEY-UHFFFAOYSA-N n-tert-butylmethanimine oxide Chemical compound CC(C)(C)[N+]([O-])=C PVMBWGUNDZTWEY-UHFFFAOYSA-N 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 abstract description 84
- 231100000844 hepatocellular carcinoma Toxicity 0.000 abstract description 84
- 230000000694 effects Effects 0.000 abstract description 52
- 210000004185 liver Anatomy 0.000 abstract description 51
- 210000003494 hepatocyte Anatomy 0.000 abstract description 28
- 230000001855 preneoplastic effect Effects 0.000 abstract description 24
- 210000004027 cell Anatomy 0.000 abstract description 16
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 12
- 235000020188 drinking water Nutrition 0.000 abstract description 10
- 239000003651 drinking water Substances 0.000 abstract description 10
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract description 9
- 229960001231 choline Drugs 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 6
- 230000002950 deficient Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 239000002207 metabolite Substances 0.000 abstract description 2
- JYIYPKOJFKMEKS-UHFFFAOYSA-N n-(2,2-dimethyl-1-phenylpropylidene)hydroxylamine Chemical compound CC(C)(C)C(=NO)C1=CC=CC=C1 JYIYPKOJFKMEKS-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000024121 nodulation Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 64
- 230000003902 lesion Effects 0.000 description 52
- 206010016654 Fibrosis Diseases 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 20
- 230000035755 proliferation Effects 0.000 description 18
- 230000004761 fibrosis Effects 0.000 description 17
- 230000006698 induction Effects 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 12
- 230000036542 oxidative stress Effects 0.000 description 12
- 230000011664 signaling Effects 0.000 description 11
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 230000001767 chemoprotection Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 208000004930 Fatty Liver Diseases 0.000 description 7
- 206010019708 Hepatic steatosis Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000010706 fatty liver disease Diseases 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000004792 oxidative damage Effects 0.000 description 7
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical compound ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 6
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 6
- 108091093105 Nuclear DNA Proteins 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 239000000306 component Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002062 proliferating effect Effects 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 150000008575 L-amino acids Chemical class 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 208000019425 cirrhosis of liver Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 231100000357 carcinogen Toxicity 0.000 description 4
- 239000003183 carcinogenic agent Substances 0.000 description 4
- 238000013243 choline-deficient amino acid-defined model Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003005 anticarcinogenic agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 235000020940 control diet Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 108700024542 myc Genes Proteins 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000000846 Bartlett's test Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000005756 apoptotic signaling Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000007253 cellular alteration Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000002113 chemopreventative effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000036732 histological change Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008599 nitrosative stress Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000006950 reactive oxygen species formation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- OIRQROBVKNWIIW-AIBWNMTMSA-N 2-[(1s)-1,2-dihydroxyethyl]-3-hydroxy-4-octadecoxy-2h-furan-5-one Chemical compound CCCCCCCCCCCCCCCCCCOC1=C(O)C([C@@H](O)CO)OC1=O OIRQROBVKNWIIW-AIBWNMTMSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 208000004481 Choline Deficiency Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- UTGQNNCQYDRXCH-UHFFFAOYSA-N N,N'-diphenyl-1,4-phenylenediamine Chemical compound C=1C=C(NC=2C=CC=CC=2)C=CC=1NC1=CC=CC=C1 UTGQNNCQYDRXCH-UHFFFAOYSA-N 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 229940124444 chemoprotective agent Drugs 0.000 description 1
- 208000021752 choline deficiency disease Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008519 endogenous mechanism Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000806 hepatocarcinogenicity Toxicity 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013319 spin trapping Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19357200P | 2000-03-30 | 2000-03-30 | |
| PCT/US2001/010508 WO2001074349A1 (en) | 2000-03-30 | 2001-03-28 | Butylnitrone containing compositons for inhibition of cancer development |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500411A true JP2004500411A (ja) | 2004-01-08 |
| JP2004500411A5 JP2004500411A5 (enExample) | 2008-05-15 |
Family
ID=22714183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001572094A Pending JP2004500411A (ja) | 2000-03-30 | 2001-03-28 | 癌の発達の阻害のための、ブチルニトロンを含む組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6569902B2 (enExample) |
| EP (1) | EP1267860A1 (enExample) |
| JP (1) | JP2004500411A (enExample) |
| AU (1) | AU785365B2 (enExample) |
| CA (1) | CA2404291A1 (enExample) |
| WO (1) | WO2001074349A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059638A1 (en) * | 2003-08-04 | 2005-03-17 | Kelly Michael G. | Aryl, heteroaromatic and bicyclic aryl nitrone compounds, prodrugs and pharmaceutical compositions of the same to treat human disorders |
| US20050182060A1 (en) * | 2004-02-13 | 2005-08-18 | Kelly Michael G. | 2-Substituted and 4-substituted aryl nitrone compounds |
| US20060235370A1 (en) * | 2005-04-04 | 2006-10-19 | Oblong John E | Method of regulating mammalian keratinous tissue |
| EP1922075A4 (en) * | 2005-08-04 | 2009-10-14 | Oklahoma Med Res Found | ADJUVANT CHEMOTHERAPY FOR ANAPLASTIC GLIOMAS |
| JP5236641B2 (ja) * | 2006-07-25 | 2013-07-17 | ハフ イヤ インスティテュート | 急性音響外傷の治療方法 |
| CA2735859C (en) | 2008-09-02 | 2016-08-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl tert-butyl nitrone for the treatment of gliomas |
| CN110373380B (zh) * | 2019-06-14 | 2022-01-28 | 中国科学院生态环境研究中心 | 一种肝脏类器官模型及其建立方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0925263A (ja) * | 1989-10-17 | 1997-01-28 | Oklahoma Medical Res Found | 酸化的損傷に伴う疾患を阻止する化合物 |
-
2001
- 2001-03-28 EP EP01920909A patent/EP1267860A1/en not_active Ceased
- 2001-03-28 AU AU47915/01A patent/AU785365B2/en not_active Ceased
- 2001-03-28 JP JP2001572094A patent/JP2004500411A/ja active Pending
- 2001-03-28 WO PCT/US2001/010508 patent/WO2001074349A1/en not_active Ceased
- 2001-03-28 CA CA002404291A patent/CA2404291A1/en not_active Abandoned
- 2001-03-28 US US09/819,570 patent/US6569902B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0925263A (ja) * | 1989-10-17 | 1997-01-28 | Oklahoma Medical Res Found | 酸化的損傷に伴う疾患を阻止する化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020004531A1 (en) | 2002-01-10 |
| US6569902B2 (en) | 2003-05-27 |
| CA2404291A1 (en) | 2001-10-11 |
| WO2001074349A1 (en) | 2001-10-11 |
| AU785365B2 (en) | 2007-02-08 |
| EP1267860A1 (en) | 2003-01-02 |
| AU4791501A (en) | 2001-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Okuda et al. | Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein | |
| Fan et al. | Malvidin protects against lipopolysaccharide-induced acute liver injury in mice via regulating Nrf2 and NLRP3 pathways and suppressing apoptosis and autophagy | |
| Yin et al. | Wedelolactone activates the PI3K/AKT/NRF2 and SLC7A11/GPX4 signalling pathways to alleviate oxidative stress and ferroptosis and improve sepsis-induced liver injury | |
| WO2023088086A1 (zh) | 组合因子及其应用 | |
| US9511104B2 (en) | Anti-cancer extract and compounds | |
| Zuo et al. | Compound IMM‐H004, a Novel Coumarin Derivative, Protects against CA 1 Cell Loss and Spatial Learning Impairments Resulting from Transient Global Ischemia | |
| Duncan et al. | Rubella Virus-Induced Apoptosis Varies among Cell Lines and Is Modulated by Bcl-XLand Caspase Inhibitors | |
| Chen et al. | Bcl-xL is required for the protective effects of low-dose berberine against doxorubicin-induced cardiotoxicity through blocking apoptosis and activating mitophagy-mediated ROS elimination | |
| Chen et al. | Methylated urolithin A, mitigates cognitive impairment by inhibiting NLRP3 inflammasome and ameliorating mitochondrial dysfunction in aging mice | |
| Chen et al. | Synthetic imine resveratrol analog 2‐methoxyl‐3, 6‐dihydroxyl‐IRA ameliorates colitis by activating protective Nrf2 pathway and inhibiting NLRP3 expression | |
| Luo et al. | SIRT1 prevents noise-induced hearing loss by enhancing cochlear mitochondrial function | |
| Kim et al. | Avenanthramide-C shows potential to alleviate gingival inflammation and alveolar bone loss in experimental periodontitis | |
| Gao et al. | Liver-specific Bcl3 knockout alleviates acetaminophen-induced liver injury by activating Nrf2 pathway in male mice | |
| TWI849808B (zh) | 藥物組成物及化療劑用於製備治療癌症之藥物的用途 | |
| EP3858351B1 (en) | Tolperisone and eperisone for use in the treatment of pulmonary fibrosis | |
| US6569902B2 (en) | Nitrone inhibition of cancer development | |
| Wang et al. | Lysine specific demethylase 1 inhibitor alleviated lipopolysaccharide/D-galactosamine-induced acute liver injury | |
| Nakae et al. | Effects of phenyl N‐tert‐butyl nitrone and its derivatives on the early phase of hepatocarcinogenesis in rats fed a choline‐deficient, L‐amino acid‐defined diet | |
| WO2021083912A1 (en) | Combination therapy having antioxydant properties | |
| CN104411308B (zh) | 通过给予某些合成化合物治疗阿尔茨海默病的方法 | |
| JP2024538323A (ja) | 腸炎と腸癌の予防又は治療に用いる薬物 | |
| US10912741B2 (en) | Prevention of liver cancer with safranal-based formulations | |
| Li et al. | Delayed liver regeneration after partial hepatectomy in aged Nos2 knockout mice | |
| CN103356521A (zh) | 丁苯酞或其衍生物在制备治疗或预防放射性脑损伤的药物中的应用 | |
| HK40086837A (en) | Medicine for preventing or treating enteritis and intestinal cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080327 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080327 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110207 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111021 |